NCT06354257已完成1 期
A Phase 1, Open-label, Fixed Sequence, 1-way Drug-drug Interaction Study to Investigate the Pharmacokinetics of GSK3036656 and an Oral Contraceptive Containing Ethinyl Estradiol and Levonorgestrel When the Oral Contraceptive is Administered Alone and in Combination With GSK3036656 in Healthy Female Participants of Nonchildbearing Potential Aged 18-65 Years of Age
适应症
干预措施
相关药物
试验速览
- 阶段
- 1 期
- 状态
- 已完成
- 入组人数
- 20
- 试验地点
- 1
- 主要终点
- Area Under the Plasma Drug Concentration (AUC) From Time Zero Extrapolated to Infinity (AUC[0-inf]) After a Single Dose of EE and LNG
研究概览
简要总结
The purpose of this study is to provide data showing if there are any effects of GSK3036656 on a combined oral contraceptive containing Ethinyl Estradiol (EE) and Levonorgestrel (LNG), which will help inform future studies on suitable contraceptive measures to be used.
研究设计
- 研究类型
- Interventional
- 分配方式
- Non Randomized
- 干预模型
- Sequential
- 主要目的
- Prevention
- 盲法
- None
盲法说明
Open-label
入排标准
- 年龄范围
- 18 Years 至 65 Years（Adult, Older Adult）
- 性别
- Female
- 接受健康志愿者
- 是
入选标准
- •Participant was 18 to 65 years of age, inclusive, at the time of signing the informed consent.
- •Type of Participant and Disease Characteristics:
- •Participants were healthy or compensated, as determined by the investigator or medically qualified designee, based on a medical evaluation including medical history, physical examination, laboratory tests, and cardiac monitoring (history and ECG).
- •Creatinine clearance was >= 75 mL/min.
- •Echocardiogram was normal or showed normal left ventricular function; at most trace to mild valvular regurgitation was allowed, with no valvular stenosis.
- •Body weight was >= 45.0 kg (99 lbs), and body mass index was within the range 18.5 to 31.0 kg/m² (inclusive).
- •Female participants were of Nonchildbearing Potential (WONCBP).
- •Women in the following categories were considered WONCBP:
- •Permanently sterile due to one of the following procedures:
- •Documented hysterectomy.
- •Documented bilateral salpingectomy.
- •Documented bilateral oophorectomy.
- •Postmenopausal females. A postmenopausal state was defined as no menses for 12 months without an alternative medical cause.
- •A high follicle-stimulating hormone (FSH) level in the postmenopausal range could have been used to confirm a postmenopausal state in women not using hormonal contraception or hormone replacement therapy (HRT). However, in the absence of 12 months of amenorrhea, confirmation with >1 FSH measurement was required within the screening period.
- •Females on HRT and whose menopausal status was in doubt discontinued HRT >= 30 days prior to the start of Treatment Period 1 to allow confirmation of postmenopausal status before study enrolment.
- •Informed Consent:
- •Participant was capable of giving signed informed consent, which included compliance with the requirements and restrictions listed in the informed consent form (ICF) and in the protocol.
排除标准
- •Medical History:
- •History of known cardiac valve abnormalities.
- •Laboratory Assessments:
- •Presence of hepatitis B surface antigen at Screening or within 3 months prior to starting study treatment.
- •Positive hepatitis C antibody test result at Screening or within 3 months prior to starting study treatment, and positive on reflex to hepatitis C RNA.
- •Positive HIV-1 and -2 antigen/antibody immunoassay at Screening.
- •Alanine aminotransferase (ALT) > 1.5×ULN. A single repeat of ALT was allowed within a single screening period to determine eligibility.
- •Bilirubin > 1.5×ULN (isolated bilirubin > 1.5×ULN was acceptable if bilirubin was fractionated and direct bilirubin was < 35%).
- •Any acute laboratory abnormality at Screening which, in the opinion of the investigator, should have precluded participation in the study of an investigational compound.
- •Participants with haemoglobin < 8.0 g/dL.
- •Any Grade 2 to 4 laboratory abnormality at Screening-except creatine phosphokinase, lipid abnormalities, and ALT (as above)-excluded a participant unless the investigator provided a compelling explanation and had sponsor assent. A single repeat of any laboratory abnormality was allowed within a single screening period.
- •Positive test result for drugs of abuse (including marijuana), alcohol, or cotinine at Screening or before the first study dose.
- •Prior/Concomitant Therapy:
- •Participants were unable to refrain from using prescription or non-prescription drugs, including vitamins, herbal and dietary supplements (including St John's wort), within 7 days prior to the first dose and throughout the study.
- •Levothyroxine and omeprazole were allowed if participants had been on a stable dose for >= 1 month prior to Treatment Period 1 and maintained the same dose. Microgynon was administered >= 1 hour after levothyroxine or omeprazole. Other medications were allowed on a case-by-case basis with medical monitor and GSK ganfeborole team approval.
- •Participants received any vaccine within 30 days prior to study treatment.
- •Participants were unwilling to abstain from excessive consumption of caffeine, grapefruit, grapefruit juice, Seville oranges, blood oranges, pomelos, or their juices within 7 days prior to first dose through study end.
- •Participants who had undergone IVF or assisted reproductive techniques within 9 months prior to screening, were currently participating, or planned such procedures during the following year were excluded.
- •Prior/Concurrent Clinical Study Experience:
- •Participants had taken part in another clinical study within 30 days, 5 half-lives + 10 days, or 2× duration of the investigational product's biological effect (whichever was longer).
- •Study participation resulted in donation of blood or blood products > 500 mL within 56 days.
- •Diagnostic Assessments:
- •Significant arrhythmia or ECG findings, in the opinion of the investigator or GSK Medical Monitor, would have interfered with participant safety.
- •Exclusion criteria for screening ECG:
- •Heart rate < 50 or > 100 bpm
- •QTcF interval > 450 ms
- •Other Exclusion Criteria:
- •Participants with vitiligo.
- •Participants with hypertension or Type 2 diabetes that could not be controlled with diet and exercise alone.
- •History of regular alcohol consumption within 6 months of the study, defined as an average weekly intake > 14 units.
- •Use of tobacco- or nicotine-containing products within 3 months prior to Screening.
- •History of sensitivity to any study medications or components, or any allergy that, in the investigator's or medical monitor's opinion, contraindicated participation.
研究组 & 干预措施
Combined Participants Group
Experimental
Participants received a dose of Microgynon [0.03 mg Ethinyl Estradiol (EE)/0.15 mg Levonorgestrel (LNG)] on Day 1 of Treatment Period 1. In Treatment Period 2, they received GSK3036656 40 mg on Day 4 followed by GSK3036656 20 mg once daily from Day 5 to Day 14. In Treatment Period 3, participants received Microgynon (EE/LNG) along with GSK3036656 20 mg on Day 15, followed by GSK3036656 20 mg once daily from Day 16 to Day 17.
干预措施: Microgynon (Drug)
Combined Participants Group
Experimental
Participants received a dose of Microgynon [0.03 mg Ethinyl Estradiol (EE)/0.15 mg Levonorgestrel (LNG)] on Day 1 of Treatment Period 1. In Treatment Period 2, they received GSK3036656 40 mg on Day 4 followed by GSK3036656 20 mg once daily from Day 5 to Day 14. In Treatment Period 3, participants received Microgynon (EE/LNG) along with GSK3036656 20 mg on Day 15, followed by GSK3036656 20 mg once daily from Day 16 to Day 17.
干预措施: GSK3036656 (Drug)
结局指标
主要结局
Area Under the Plasma Drug Concentration (AUC) From Time Zero Extrapolated to Infinity (AUC[0-inf]) After a Single Dose of EE and LNG
时间窗: At Day 1 for the Treatment Period 1: Microgynon Group and at Day 15 for the Treatment Period 3: Microgynon + GSK3036656 Group
AUC(0-inf) is defined as the area under the concentration-time curve from time 0 extrapolated to infinity and was calculated by using a non-compartmental analysis.
Maximum Observed Plasma Concentration (Cmax) After a Single Dose of EE and LNG
时间窗: At Day 1 for the Treatment Period 1: Microgynon Group and at Day 15 for the Treatment Period 3: Microgynon + GSK3036656 Group
Cmax is defined as the maximum observed plasma concentration determined directly from the concentration-time data and was calculated by using a non-compartmental analysis.
次要结局
- Trough Plasma Concentration (Ctau) at Steady State of GSK3036656 With EE/LNG and GSK3036656 Alone(At Day 8, 10, 12, 15 and 16)
- AUC Versus Time Curve From Time Zero During a Dosage Interval of Time at Steady State [AUC(0-tau)] of GSK3036656 With EE/LNG(At Day 15)
- Cmax at Steady State of GSK3036656 With EE/LNG(At Day 15)
- Time to Maximum Observed Plasma Drug Concentration (Tmax) at Steady State of GSK3036656 With EE/LNG(At Day 15)
- AUC Versus Time Curve (AUC[0-t]) of EE and LNG Alone and With GSK3036656(At Day 1 for the Treatment Period 1: Microgynon Group and at Day 15 for the Treatment Period 3: Microgynon + GSK3036656 Group)
- Tmax of EE and LNG Alone and With GSK3036656(At Day 1 for the Treatment Period 1: Microgynon Group and at Day 15 for the Treatment Period 3: Microgynon + GSK3036656 Group)
- Apparent Terminal Half-life (t1/2) of EE and LNG Alone and With GSK3036656(At Day 1 for the Treatment Period 1: Microgynon Group and at Day 15 for the Treatment Period 3: Microgynon + GSK3036656 Group)
- Number of Participants With Serious Adverse Events (SAEs)(From the signing of the informed consent form (a period starting up to 14 days before the first dose on Day 1) up to Day 18)
- Number of Participants With Grade 3 or Higher Severity Adverse Events (AEs)(From Day 1 up to Day 18)
- Number of Participants With Drug-related AEs Following Administration of Microgynon and Following the Administration of GSK3036656(From Day 1 up to Day 18)
- Number of Participants Withdrawn From the Treatment Due to AEs(From Day 1 up to Day 18)
- Number of Participants Withdrawn From the Study Due to AEs(From Day 1 up to Day 18)
- Number of Participants With Electrocardiogram (ECG) Values of Potential Clinical Importance (PCI)(From Day 1 up to Day 18)
- Number of Participants With Clinical Chemistry Laboratory Values of PCI(From Day 1 up to Day 18)
- Number of Participants With Haematology Laboratory Values of PCI(From Day 1 up to Day 18)
- Number of Participants With Vital Signs Parameters of PCI(From Day 1 up to Day 18)
研究者
研究点 (1)
Loading locations...
相似试验
已完成
1 期
Drug Interaction Study Between GSK1349572 and Tipranavir/Ritonavir in Healthy VolunteersInfection, Human Immunodeficiency VirusHIV InfectionsNCT01068925ViiV Healthcare18
已完成
1 期
Phase 1 Study of GSK3228836 Pharmacokinetics in Participants With Hepatic ImpairmentHepatitis BNCT04971928GlaxoSmithKline24
已完成
1 期
Evaluation of Pharmacokinetic Interaction Between GSK3640254 and Caffeine, Metoprolol, Montelukast, Flurbiprofen, Omeprazole, Midazolam, Digoxin, and Pravastatin in Healthy AdultsHIV InfectionsNCT04425902ViiV Healthcare20
终止
1 期
Study to Investigate the Safety and Clinical Activity of GSK3326595 and Other Agents to Treat Myelodysplastic Syndrome (MDS) and Acute Myeloid Leukemia (AML)NeoplasmsNCT03614728GlaxoSmithKline30
已完成
1 期
GSK1349572 Drug Interaction Study With EtravirineHealthy SubjectsNCT00774111GlaxoSmithKline16